Information about Ramp Plus
Composition:
Each tablet contains either:
2.5 mg ramipril 12.5mg hydrochlorothiazide “HCT” or,
5 mg ramipril /12.5mg hydrochlorothiazide “HCT” or,
10 mg ramipril /12.5mg hydrochlorothiazide “HCT” or,
Indications:
RAMP PLUS is indicated for the treatment of essential hypertension in patients for whom this combination therapy is appropriate. Patients should be titrated on individual drugs.
If during maintenance therapy dosage adjustment is necessary, it is advisable to use the individual drugs.
Contraindications:
RAMP PLUS is contraindicated in
Patients who are hypersensitive to this drug, to any other angiotensin converting enzyme (ACE) inhibitor, or to any ingredient of the drug.
Patients who have a history of angioedema.
During pregnancy and in breast feeding women.
Patients with anuria or hypersensitivity to thiazides and other sulfonamide- derived drugs.
Side Effects:
The most frequent adverse drug reactions observed with Ramp Plus were: headache, dizziness and bronchitis. The common serious adverse event pooled from the different clinical trials was tachycardia.
Dosage and Administration:
Dosage should be individualized.
The dose of RAMP PLUS should be determined by the titration of the individual component.
Special attention for dialysis patients.
Usual dosage: 2.5mg ramipril / 12.5mg hydrochlorothiazide “HCT” daily.
Generally it is recommended that the daily dose be taken in the morning.
Titration will be based on physician’s judgment according to severity of hypotension and other associated factors.
Maximum daily dose: 10mg ramipril and 50mg hydrochlorothiazide.
Daily dose for renally impaired patients is 5mg ramipril / 25mg hydrochlorothiazide.
If a dose has been missed, it should be taken as soon as possible. But if it is almost time for the next dose, go to the regular dose and skip the missed one. No double doses.
RAMP PLUS tablets should be swallowed with a glass of liquid and not chewed or crushed.
Overdosage:
Overdosage may cause persistent diuresis, and excessive peripheral vasodilatation.
Treatment is symptomatic and supportive. Primary detoxification by adsorbents
In the event of hypotension, administration of norepinephrine, dopamine or angiotensinamide must be considered in addition to volume and substitution.
If dialysis or hemofiltration is nevertheless contemplated, the risk of anaphylactoid reactions with high flux should be considered.
Removal of thiazide diuretics by dialysis is negligible.
Storage:
RAMP PLUS is stored in the original container at room temperature, between 15o C and 30o C and not after expiry of date.
Packing:
Pack of 30 Tablets
Manufactured by: Universal Pharmaceutical Industries UNIPHARMA
Damascus – Syria.